Miyawaki, Taichi
Naito, Tateaki http://orcid.org/0000-0003-4047-2929
Yabe, Michitoshi
Kodama, Hiroaki
Nishioka, Naoya
Miyawaki, Eriko
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Wakuda, Kazushige
Ono, Akira
Kenmotsu, Hirotsugu
Murakami, Haruyasu
Mori, Keita
Harada, Hideyuki
Takahashi, Kazuhisa
Takahashi, Toshiaki
Article History
Received: 14 May 2021
Accepted: 10 September 2021
First Online: 22 September 2021
Declarations
:
: The ethical review board of our institution approved the study (registration no. J2020-176–2020-1). All procedures performed in studies involving human participants were in accordance with 1964 Helsinki declaration and its later amendments or with comparable ethical standards.
: For this type of study, formal consent is not required. However, we also employed an opt-out method to obtain consent for this study by posting a document about this study. The document has been approved by the institutional ethics review board of Shizuoka Cancer Center.
: Not applicable.
: Dr. Taichi Miyawaki — Declarations of interest: none.Dr. Naito, Dr. Yabe, Dr. Kodama, Dr. Nishioka, Dr. Eriko Miyawaki, Dr. Mori — Declarations of interest: none.Dr. Mamesaya reports personal fees from AstraZeneca KK, Pfizer Japan, Inc.; personal fees from Chugai Pharmaceutical Co., Ltd.; grants and personal fees from Boehringer Ingelheim; personal fees from MSD K.K.; personal fees from TAIHO PHARMACEUTICAL CO., LTD.; and personal fees from ONO PHARMACEUTICAL CO., LTD., outside the submitted work.Dr. Kobayashi reports personal fees from Eli Lilly K.K, personal fees from Taiho Pharmaceutical, personal fees from AstraZeneca, outside the submitted work.Dr. Omori reports personal fees from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical, AstraZeneca K.K., Boehringer Ingelheim, Taiho Pharmaceutical, and MSD, which are unrelated to the submitted work.Dr. Wakuda reports grants and personal fees from Chugai Pharmaceutical Co., Ltd.; personal fees from Taiho Pharmaceutical; personal fees from Boehringer Ingelheim; personal fees from Eli Lilly K.K.; personal fees from Ono Pharmaceutical, personal fees from MSD; grants from Novartis; grants from Abbvie; and grants and personal fees from AstraZeneca, outside the submitted work.Dr. Ono reports grants from Taiho Pharmaceutical, grants from Ono Pharmaceutical, grants from Chugai Pharmaceutical Co., Ltd., and grants from Novartis Pharma K.K., outside the submitted work.Dr. Kenmotsu reports grants and personal fees from Chugai Pharmaceutical Co, Ltd.; personal fees from Ono Pharmaceutical Co, Ltd.; personal fees from Boeringer Ingelheim; personal fees from Eli Lilly K.K; personal fees from Kyowa Hakko Kirin Co., Ltd.; personal fees from Bristol-Myers Squibb; personal fees from MSD; grants and personal fees from Novartis Pharma K.K.; grants and personal fees from Daiichi-Sankyo Co., Ltd.; grants and personal fees from AstraZeneca K.K.; personal fees from Pfizer; and personal fees from Taiho Pharma, outside the submitted work.Dr. Murakami reports personal fees from AstraZeneca K.K., Ono Pharmaceutical, Bristol-Myers Squibb Japan, Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Novartis Pharma K.K., Boehringer Ingelheim, Taiho Pharmaceutical, Eli Lilly K.K., and MSD, which are unrelated to the submitted work.Dr. Harada reports personal fees from Daiichi Sankyo Pharmaceutical Co. during the conduct of the study as well as personal fees from Daiichi Sankyo Pharmaceutical Co., AstraZeneca K.K., Brain Labo Co., and Chugai Pharmaceutical Co. and grants from the Japan Agency for Medical Research and Development and the National Cancer Center Research and Development Fund, which are unrelated to the submitted work.Dr. Kazuhisa Takahashi reports grants and personal fees from AstraZeneca K.K., Pfizer Japan, Inc., Eli Lilly K.K., MSD, and Boehringer Ingelheim as well as grants from Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., GlaxoSmithKline Consumer Healthcare Japan K.K., SHIONOGI & CO., LTD., and Novartis Pharma K.K., which are unrelated to the submitted work.Dr. Toshiaki Takahashi reports grants and personal fees from AstraZeneca KK, Pfizer Japan, Inc.; grants and personal fees from Eli Lilly Japan K.K.; grants and personal fees from Chugai Pharmaceutical Co., Ltd.; grants and personal fees from Ono Pharmaceutical Co., Ltd.; grants and personal fees from MSD K.K.; grants and personal fees from Boehringer Ingelheim Japan, Inc.; grants and personal fees from Pfizer Japan, Inc.; and personal fees from Roche Diagnostics K.K., outside the submitted work.